Spots Global Cancer Trial Database for metastatic urothelial carcinoma

Every month we try and update this database with for metastatic urothelial carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study of NX-1607 in Adults With Advanced Malignancies	NCT05107674	Ovarian Cancer,... Gastric Cancer GastroEsophagea... Head and Neck S... Metastatic or U... Non-small Cell ... Metastatic Cast... Malignant Pleur... Triple Negative... Metastatic Urot... Cervical Cancer Diffuse Large B... Richter Transfo... Microsatellite ...	NX-1607 Paclitaxel	18 Years -	Nurix Therapeutics, Inc.
A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer	NCT04839510	Locally Advance... Metastatic Urot...	MRG002	18 Years - 75 Years	Shanghai Miracogen Inc.
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer	NCT02351739	Metastatic Urot...	pembrolizumab ACP-196 in comb...	18 Years -	Acerta Pharma BV
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer	NCT04639245	Anatomic Stage ... Metastatic Lung... Metastatic Mali... Metastatic Trip... Metastatic Urot... Stage IV Lung C...	Atezolizumab Cyclophosphamid... Fludarabine MAGE-A1-specifi... PD1 Inhibitor	18 Years -	Fred Hutchinson Cancer Center
A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma	NCT04486781	Metastatic Urot...	Pembrolizumab +...	18 Years -	Vasgene Therapeutics, Inc
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer	NCT04878029	Infiltrating Bl... Locally Advance... Metastatic Urot... Unresectable Ur...	Cabozantinib S-... Enfortumab Vedo... Quality-of-Life... Questionnaire A...	18 Years -	Emory University
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers	NCT04388852	Aggressive Vari... Castration-Resi... Metastatic Clea... Metastatic Mali... Metastatic Pros... Metastatic Urot... Stage IV Prosta... Stage IV Renal ... Stage IVA Prost... Stage IVB Prost...	Ipilimumab Valemetostat	18 Years -	M.D. Anderson Cancer Center
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies	NCT03590054	Stage III Cutan... Stage IV Cutane... Locally Advance... Locally Advance... Metastatic Head... Metastatic Mali... Metastatic Mela... Metastatic Urot... Non-Small Cell ... Stage IB Lung C... Stage III Cutan... Stage III Lung ... Stage III Urete... Stage IIIA Lung... Stage IIIB Lung... Stage IIIC Lung... Stage IV Cutane... Stage IV Lung C... Stage IV Ureter... Stage IVA Lung ... Stage IVB Lung ...	Abexinostat Pembrolizumab	18 Years -	University of California, San Francisco
Study of OB-002 in Patients With Refractory Metastatic Cancer	NCT05940844	Metastatic Canc... Metastatic Colo... Metastatic Panc... Metastatic Gast... Metastatic Brea... Metastatic Urot...	OB-002	18 Years -	Orion Biotechnology Polska Sp. z o.o.
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV	NCT04514484	Advanced Differ... Advanced Head a... Advanced Hepato... Advanced Kaposi... Advanced Lung N... Advanced Lung S... Advanced Malign... Advanced Melano... Advanced Ovaria... Advanced Prosta... Advanced Renal ... Advanced Thyroi... Advanced Triple... Advanced Urothe... Anatomic Stage ... Anatomic Stage ... Castration-Resi... Clinical Stage ... Clinical Stage ... HIV Infection Metastatic Diff... Metastatic Head... Metastatic Hepa... Metastatic Kapo... Metastatic Lung... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Ovar... Metastatic Pros... Metastatic Rena... Metastatic Thyr... Metastatic Trip... Metastatic Urot... Recurrent Diffe... Recurrent Head ... Recurrent Hepat... Recurrent Kapos... Recurrent Lung ... Recurrent Lung ... Recurrent Malig... Recurrent Melan... Recurrent Ovari... Recurrent Prost... Recurrent Renal... Recurrent Thyro... Recurrent Tripl... Recurrent Uroth... Refractory Diff... Stage III Diffe... Stage III Hepat... Stage III Lung ... Stage III Ovari... Stage III Prost... Stage III Renal... Stage III Thyro... Stage IV Differ... Stage IV Hepato... Stage IV Lung C... Stage IV Ovaria... Stage IV Prosta... Stage IV Renal ... Stage IV Thyroi...	Biospecimen Col... Cabozantinib S-... Computed Tomogr... Magnetic Resona... Nivolumab	18 Years -	National Cancer Institute (NCI)
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma	NCT03513952	Advanced Bladde... Advanced Ureter... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Unresectable Bl... Unresectable Re... Unresectable Ur...	Atezolizumab Biopsy Biospecimen Col... Computed Tomogr... Glycosylated Re... Laboratory Biom... Magnetic Resona... Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy	NCT04963153	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr...	Biospecimen Col... Computed Tomogr... Enfortumab Vedo... Erdafitinib	18 Years -	National Cancer Institute (NCI)
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer	NCT02351739	Metastatic Urot...	pembrolizumab ACP-196 in comb...	18 Years -	Acerta Pharma BV
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma	NCT03397394	Bladder Cancer Urothelial Carc... Metastatic Urot... Renal Pelvis Ca... Ureter Carcinom... Urinary Bladder... Urethra Carcino... Muscle Invasive...	Rucaparib	18 Years -	pharmaand GmbH
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers	NCT03115801	Metastatic Rena... Metastatic Urot...	Nivolumab Atezolizumab Radiation & imm... Pembrolizumab	19 Years - 90 Years	Weill Medical College of Cornell University
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib	NCT05052372	Bladder Cancer Urothelial Carc... Transitional Ce... Platinum-Resist... Bladder Urothel... FGFR Mutation FGFR2 Gene Muta... FGFR3 Gene Muta... FGFR2 Amplifica... Locally Advance... Metastatic Urot... Refractory Blad... Refractory Blad...	Balversa	18 Years -	xCures
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors	NCT03682289	Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Metastatic Urot... Metastatic Panc... Stage III Pancr... Stage III Renal... Stage IV Pancre... Stage IV Renal ... Endometrial Can... Metastatic Cast...	Ceralasertib Olaparib Durvalumab	18 Years -	University of California, San Francisco
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression	NCT04953104	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur... Unresectable Ur...	Diagnostic Labo... Nivolumab Relatlimab	18 Years -	M.D. Anderson Cancer Center
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma	NCT04856189	Advanced Urothe... Locally Advance... Metastatic Urot... Refractory Urot...	Pembrolizumab Selinexor	18 Years -	University of California, Davis
Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer	NCT02693717	Metastatic Urot...	Laboratory Biom... Pemetrexed Diso...	18 Years -	M.D. Anderson Cancer Center
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers	NCT03115801	Metastatic Rena... Metastatic Urot...	Nivolumab Atezolizumab Radiation & imm... Pembrolizumab	19 Years - 90 Years	Weill Medical College of Cornell University
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression	NCT04953104	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur... Unresectable Ur...	Diagnostic Labo... Nivolumab Relatlimab	18 Years -	M.D. Anderson Cancer Center
Sacituzumab Govitecan Plus EV in Metastatic UC	NCT04724018	Urothelial Canc... Metastatic Urot... Metastatic Urot... Bladder Cancer	Sacituzumab Gov... Enfortumab vedo...	18 Years -	Dana-Farber Cancer Institute
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations	NCT03047213	Locally Advance... Metastatic Tran... Metastatic Urot... Recurrent Bladd... Stage III Bladd... Stage IV Bladde...	Sapanisertib	18 Years -	National Cancer Institute (NCI)
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma	NCT03534804	Metastatic Urot... Bladder Cancer	Cabozantinib Pembrolizumab	18 Years -	University of Utah
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers	NCT03115801	Metastatic Rena... Metastatic Urot...	Nivolumab Atezolizumab Radiation & imm... Pembrolizumab	19 Years - 90 Years	Weill Medical College of Cornell University
SOGUG-AVELUMAB_RWD	NCT05700344	Metastatic Urot...	Avelumab	18 Years - 120 Years	Spanish Oncology Genito-Urinary Group
INJECT: A Pilot Study of Intra-tumoral Injections in Metastatic Urological Cancers	NCT03071328	Metastatic Cast... Metastatic Urot... Metastatic Rena...	Isovue-M 200	18 Years -	Duke University
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors	NCT05733000	Advanced Biliar... Advanced Colore... Advanced Gastro... Advanced Lung A... Advanced Malign... Advanced Ovaria... Advanced Pancre... Advanced Urothe... Clinical Stage ... Clinical Stage ... Metastatic Bili... Metastatic Colo... Metastatic Gast... Metastatic Lung... Metastatic Ovar... Metastatic Panc... Metastatic Urot... Refractory Bili... Refractory Colo... Refractory Gast... Refractory Lung... Refractory Ovar... Refractory Panc... Refractory Urot... Stage II Pancre... Stage III Color... Stage III Lung ... Stage III Ovari... Stage III Pancr... Stage IV Colore... Stage IV Lung C... Stage IV Ovaria... Stage IV Pancre...	Biospecimen Col... Computed Tomogr... Devimistat Fluorouracil Gemcitabine Hyd... Hydroxychloroqu... Magnetic Resona...	18 Years -	Northwestern University
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib	NCT05052372	Bladder Cancer Urothelial Carc... Transitional Ce... Platinum-Resist... Bladder Urothel... FGFR Mutation FGFR2 Gene Muta... FGFR3 Gene Muta... FGFR2 Amplifica... Locally Advance... Metastatic Urot... Refractory Blad... Refractory Blad...	Balversa	18 Years -	xCures
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma	NCT05923190	Urothelial Carc... Metastatic Urot... Locally Advance...	Enfortumab vedo... Pembrolizumab	18 Years -	Fox Chase Cancer Center
SOGUG-AVELUMAB_RWD	NCT05700344	Metastatic Urot...	Avelumab	18 Years - 120 Years	Spanish Oncology Genito-Urinary Group
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction	NCT00365157	Advanced Urothe... Locally Advance... Metastatic Urot... Recurrent Uroth... Stage III Bladd... Stage IV Bladde... Unresectable Ur...	Eribulin Mesyla... Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma	NCT04856189	Advanced Urothe... Locally Advance... Metastatic Urot... Refractory Urot...	Pembrolizumab Selinexor	18 Years -	University of California, Davis
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program	NCT06265285	Advanced Esopha... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Esophageal Carc... Gastroesophagea... Hepatocellular ... Locally Advance... Lung Non-Small ... Malignant Solid... Metastatic Colo... Metastatic Cuta... Metastatic Esop... Metastatic Head... Metastatic Urot... Recurrent Esoph... Recurrent Head ... Renal Cell Carc... Stage III Renal... Stage IV Colore... Stage IV Cutane... Stage IV Renal ... Unresectable Cu... Unresectable Es... Urothelial Carc...	Home Health Enc... Nivolumab Patient Monitor... Questionnaire A...	18 Years -	Mayo Clinic
A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients	NCT04383067	Metastatic Urot...	Tumor Infiltrat... Proleukin	18 Years -	Sheba Medical Center
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	NCT04007744	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Head... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Urot... Recurrent Head ... Refractory Lung... Stage IV Cutane... Stage IV Lung C... Unresectable Ma... Unresectable Me...	Pembrolizumab Sonidegib	18 Years -	Mayo Clinic
Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma	NCT05154994	Infiltrating Ur... Locally Advance... Metastatic Urot... Unresectable Ur...	Belinostat Durvalumab	18 Years -	University of Utah
Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy	NCT06439836	Metastatic Urot... Unresectable Ur...	Biopsy Biospecimen Col... Computed Tomogr... Emavusertib Magnetic Resona... Pembrolizumab Positron Emissi...	18 Years -	National Cancer Institute (NCI)
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)	NCT04003610	Metastatic Urot... Unresectable Ur...	Pemigatinib Pembrolizumab Gemcitabine Carboplatin	18 Years -	Incyte Corporation
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression	NCT04953104	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur... Unresectable Ur...	Diagnostic Labo... Nivolumab Relatlimab	18 Years -	M.D. Anderson Cancer Center
A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients	NCT04383067	Metastatic Urot...	Tumor Infiltrat... Proleukin	18 Years -	Sheba Medical Center
Study of OB-002 in Patients With Refractory Metastatic Cancer	NCT05940844	Metastatic Canc... Metastatic Colo... Metastatic Panc... Metastatic Gast... Metastatic Brea... Metastatic Urot...	OB-002	18 Years -	Orion Biotechnology Polska Sp. z o.o.
A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer	NCT05699135	Urinary Bladder... Bladder Cancer Bladder Tumors Urothelial Carc...	Avelumab first-...	18 Years -	Pfizer
Urine Omics Predicting IO Therapy Responses in mUC Patients	NCT04641936	Metastatic Urot...	No intervention...	20 Years -	National Taiwan University Hospital
Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma	NCT05923190	Urothelial Carc... Metastatic Urot... Locally Advance...	Enfortumab vedo... Pembrolizumab	18 Years -	Fox Chase Cancer Center
Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma	NCT03464734	Metastatic Urot...	Pembrolizumab a...	18 Years -	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Urine Omics Predicting IO Therapy Responses in mUC Patients	NCT04641936	Metastatic Urot...	No intervention...	20 Years -	National Taiwan University Hospital
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer	NCT04936230	Metastatic Urot... Platinum-Resist... Stage IV Bladde...	Biospecimen Col... Bone Scan Computed Tomogr... Magnetic Resona... Pembrolizumab Positron Emissi... Questionnaire A... Stereotactic Bo...	18 Years -	National Cancer Institute (NCI)
Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer	NCT02351739	Metastatic Urot...	pembrolizumab ACP-196 in comb...	18 Years -	Acerta Pharma BV
A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer	NCT05699135	Urinary Bladder... Bladder Cancer Bladder Tumors Urothelial Carc...	Avelumab first-...	18 Years -	Pfizer
Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy	NCT04637594	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot...	Pembrolizumab Nivolumab Atezolizumab Durvalumab Avelumab	18 Years -	Alliance for Clinical Trials in Oncology
A Study to Compare the Results of FGFR Testing by Either ctDNA Blood Testing or Standard Tumor Tissue Testing	NCT06129084	Metastatic Blad... Metastatic Urot...	FGFR Testing	18 Years -	British Columbia Cancer Agency
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer	NCT04639245	Anatomic Stage ... Metastatic Lung... Metastatic Mali... Metastatic Trip... Metastatic Urot... Stage IV Lung C...	Atezolizumab Cyclophosphamid... Fludarabine MAGE-A1-specifi... PD1 Inhibitor	18 Years -	Fred Hutchinson Cancer Center
Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer	NCT03744793	Infiltrating Bl... Infiltrating Bl... Infiltrating Bl... Infiltrating Bl... Infiltrating Bl... Metastatic Urot... MTAP Negative	Avelumab Pemetrexed	18 Years -	M.D. Anderson Cancer Center
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma	NCT03534804	Metastatic Urot... Bladder Cancer	Cabozantinib Pembrolizumab	18 Years -	University of Utah
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma	NCT04848519	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr...	Pembrolizumab Propranolol Hyd... Nivolumab Avelumab	18 Years -	Emory University
Nivolumab for the Treatment of Patients With Metastatic Urothelial Cancer With ARID1A Mutation and Stratify Response Based on CXCL13 Expression	NCT04953104	Locally Advance... Locally Advance... Locally Advance... Locally Advance... Locally Advance... Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Recurrent Bladd... Recurrent Renal... Recurrent Urete... Recurrent Ureth... Recurrent Uroth... Stage III Bladd... Stage III Renal... Stage III Urete... Stage III Ureth... Stage IIIA Blad... Stage IIIB Blad... Stage IV Bladde... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd... Unresectable Bl... Unresectable Re... Unresectable Ur... Unresectable Ur... Unresectable Ur...	Diagnostic Labo... Nivolumab Relatlimab	18 Years -	M.D. Anderson Cancer Center
A Phase 2, Single-Center, Open Label Study of Autologous, Adoptive Cell Therapy Following a Reduced Intensity, Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Urothelial Carcinoma Patients	NCT04383067	Metastatic Urot...	Tumor Infiltrat... Proleukin	18 Years -	Sheba Medical Center
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer	NCT00942331	Advanced Urothe... Metastatic Blad... Metastatic Pros... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Stage IV Bladde... Stage IV Prosta... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Unresectable Ur...	Bevacizumab Cisplatin Gemcitabine Hyd... Laboratory Biom... Placebo Adminis...	18 Years -	National Cancer Institute (NCI)
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial	NCT04693377	Castration-Resi... Metastatic Colo... Metastatic Mali... Metastatic Mali... Metastatic Mela... Metastatic Pros... Metastatic Rena... Metastatic Sarc... Metastatic Thyr... Metastatic Urot... Stage IV Colore... Stage IV Prosta... Stage IV Renal ... Stage IVA Color... Stage IVA Prost... Stage IVB Color... Stage IVB Prost... Stage IVC Color...	Cryosurgery Quality-of-Life... Stereotactic Bo...	18 Years -	M.D. Anderson Cancer Center
A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer	NCT03785925	Urinary Bladder... Neoplasm Metast...	Bempegaldesleuk... Nivolumab	18 Years -	Nektar Therapeutics
Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations	NCT03047213	Locally Advance... Metastatic Tran... Metastatic Urot... Recurrent Bladd... Stage III Bladd... Stage IV Bladde...	Sapanisertib	18 Years -	National Cancer Institute (NCI)
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors	NCT04007744	Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Locally Advance... Locally Advance... Locally Advance... Metastatic Gast... Metastatic Gast... Metastatic Head... Metastatic Lung... Metastatic Mali... Metastatic Mela... Metastatic Urot... Recurrent Head ... Refractory Lung... Stage IV Cutane... Stage IV Lung C... Unresectable Ma... Unresectable Me...	Pembrolizumab Sonidegib	18 Years -	Mayo Clinic
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors	NCT03682289	Clear Cell Rena... Locally Advance... Locally Advance... Metastatic Mali... Metastatic Rena... Metastatic Urot... Metastatic Panc... Stage III Pancr... Stage III Renal... Stage IV Pancre... Stage IV Renal ... Endometrial Can... Metastatic Cast...	Ceralasertib Olaparib Durvalumab	18 Years -	University of California, San Francisco
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer	NCT04579224	Metastatic Blad... Metastatic Rena... Metastatic Uret... Metastatic Uret... Metastatic Urot... Refractory Blad... Refractory Rena... Refractory Uret... Refractory Uret... Refractory Urot... Stage IV Bladde... Stage IV Renal ... Stage IV Renal ... Stage IV Ureter... Stage IV Urethr... Stage IVA Bladd... Stage IVB Bladd...	Biospecimen Col... Bone Scan Computed Tomogr... Docetaxel Eribulin Mesyla... Gemcitabine Hyd... Magnetic Resona... Paclitaxel Sacituzumab Gov...	18 Years -	National Cancer Institute (NCI)
Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program	NCT06265285	Advanced Esopha... Advanced Renal ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Clinical Stage ... Esophageal Carc... Gastroesophagea... Hepatocellular ... Locally Advance... Lung Non-Small ... Malignant Solid... Metastatic Colo... Metastatic Cuta... Metastatic Esop... Metastatic Head... Metastatic Urot... Recurrent Esoph... Recurrent Head ... Renal Cell Carc... Stage III Renal... Stage IV Colore... Stage IV Cutane... Stage IV Renal ... Unresectable Cu... Unresectable Es... Urothelial Carc...	Home Health Enc... Nivolumab Patient Monitor... Questionnaire A...	18 Years -	Mayo Clinic
An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy	NCT04623502	Kidney Cancer Renal Cell Carc... Clear Cell Carc... Urothelial Carc... Metastatic Kidn... Metastatic Urot... Papillary Renal... Chromophobe Ren... Fumarate Hydrat... Succinate Dehyd... HLRCC Hereditary Leio...	13C-Glucose 13C-Acetate 13C-Lactate 13C-Glutamine 13C-Fructose	18 Years -	University of Texas Southwestern Medical Center
Ixazomib Citrate With Gemcitabine Hydrochloride and Doxorubicin Hydrochloride in Treating Patients With Urothelial Cancer That is Metastatic or Cannot Be Removed by Surgery	NCT02420847	Metastatic Urot... Transitional Ce... Unresectable Tr...	Doxorubicin Hyd... Gemcitabine Hyd... Ixazomib Citrat...	18 Years -	M.D. Anderson Cancer Center
Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer	NCT04878029	Infiltrating Bl... Locally Advance... Metastatic Urot... Unresectable Ur...	Cabozantinib S-... Enfortumab Vedo... Quality-of-Life... Questionnaire A...	18 Years -	Emory University
A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)	NCT06050954	Metastatic Urot...	Pembrolizumab (... Pembrolizumab (... Monitoring	18 Years -	Fox Chase Cancer Center
Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma	NCT03534804	Metastatic Urot... Bladder Cancer	Cabozantinib Pembrolizumab	18 Years -	University of Utah
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients	NCT04863885	Metastatic Urot...	Ipilimumab Nivolumab Sacituzumab gov...	18 Years -	H. Lee Moffitt Cancer Center and Research Institute

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: